rajasekharkakarla
☆    

India,
2019-09-20 08:35
(2474 d 19:19 ago)

Posting: # 20628
Views: 2,932
 

 Reference replicated designs [Regulatives / Guidelines]

Post reply
Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar
 
UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
156 visitors (0 registered, 156 guests [including 23 identified bots]).
Forum time: 03:55 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5